Olivia Simpson
Reproductive Endocrinology/Infertility · Moultrie, GANPI 1497214654
Payments from drug & device makers
Across 81 payments — averaging $45.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Novartis$409
- Bayer$111
- Merck$102
- E.r. Squibb & Sons, L.L.C.$76
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$70
- plus $487 from 15 others
What the payments were for
- Travel & lodging$1,47340%
- Food & beverage$2,24160%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 19 | $2,458 |
| Novartis | 19 | $409 |
| Bayer | 5 | $111 |
| Merck | 5 | $102 |
| E.r. Squibb & Sons, L.L.C. | 3 | $76 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $70 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $66 |
| Vital Connect, Inc | 2 | $61 |
| Novo Nordisk | 3 | $59 |
| Scpharmaceuticals Inc. | 3 | $57 |
| Bridgebio Pharma, Inc. | 2 | $42 |
| Kestra Medical Technology Services, Inc. | 2 | $27 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $25 |
| Philips North America LLC | 1 | $22 |
| AbbVie | 1 | $21 |
| Pfizer | 1 | $21 |
| Boehringer Ingelheim | 1 | $21 |
| AstraZeneca | 1 | $19 |
| Alnylam Pharmaceuticals Inc. | 1 | $17 |
| Abbott | 1 | $16 |
| Amgen | 1 | $14 |
How this compares
Too few reproductive endocrinology/infertility providers in Georgiato place this figure against a meaningful peer group, so we don't.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 46 | $57,145 |
| JardianceEmpagliflozin | 19 | $30,335 |
| EntrestoSacubitril/Valsartan | 17 | $20,515 |
| Repatha SureclickEvolocumab | 27 | $18,052 |
| BrilintaTicagrelor | 12 | $13,301 |
| Ranolazine ErRanolazine | 27 | $2,992 |
| Nitroglycerin | 133 | $2,267 |
| Metoprolol Succinate | 144 | $1,712 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 148 | $1,268 |
| Rosuvastatin Calcium | 79 | $1,248 |
| Atorvastatin Calcium | 130 | $1,192 |
| Midodrine Hcl | 22 | $1,128 |
| Ezetimibe | 76 | $999 |
| Nebivolol Hcl | 14 | $994 |
| ClopidogrelClopidogrel Bisulfate | 90 | $862 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $21 | $57,14546 claims |
| Boehringer IngelheimJardiance | $21 | $30,33519 claims |
| NovartisEntresto | $409 | $20,51517 claims |
| AstraZenecaBrilinta | $19 | $13,30112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few reproductive endocrinology/infertility providers in Georgiaon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.